Technical Trend Overview and Price Movement
On 11 March 2026, Alkem Laboratories Ltd closed at ₹5,619.05, marking a significant intraday gain of 2.91% from the previous close of ₹5,460.20. The stock traded within a range of ₹5,461.00 to ₹5,656.00, nearing its 52-week high of ₹5,933.00, while comfortably above its 52-week low of ₹4,609.50. This price action reflects a strengthening momentum after a period of consolidation.
The technical trend has shifted from sideways to mildly bullish, supported by daily moving averages that have started to slope upwards, signalling potential continuation of the upward trajectory. This is a positive development for traders who rely on moving averages as a trend confirmation tool.
MACD Signals: Divergent Weekly and Monthly Perspectives
The Moving Average Convergence Divergence (MACD) indicator presents a nuanced picture. On a weekly timeframe, the MACD remains mildly bearish, indicating some short-term caution among market participants. However, the monthly MACD has turned bullish, suggesting that the longer-term momentum is improving and may support sustained gains in the coming months.
This divergence between weekly and monthly MACD readings implies that while short-term volatility and profit-taking could persist, the broader trend favours accumulation and strength in Alkem Laboratories’ shares.
RSI and Bollinger Bands: Neutral to Mildly Bullish Signals
The Relative Strength Index (RSI) on both weekly and monthly charts currently shows no definitive signal, hovering in neutral territory. This indicates that the stock is neither overbought nor oversold, providing room for further price appreciation without immediate risk of a sharp reversal.
Bollinger Bands reinforce this view, with weekly bands reflecting sideways movement, while monthly bands have turned mildly bullish. The expansion of the bands on the monthly scale suggests increasing volatility with a positive bias, which often precedes a breakout in price.
Handpicked from 50, scrutinized by experts – Our recent selection, this Mid Cap from Bank - Public, is already delivering results. Don't miss next month's pick!
- - Expert-scrutinized selection
- - Already delivering results
- - Monthly focused approach
Other Technical Indicators: KST, Dow Theory, and OBV
The Know Sure Thing (KST) indicator remains mildly bearish on both weekly and monthly timeframes, signalling some underlying weakness in momentum that investors should monitor closely. Similarly, Dow Theory assessments show a mildly bearish trend on the weekly chart and no clear trend on the monthly chart, reflecting a market in transition.
On-Balance Volume (OBV) does not currently indicate any significant trend on either weekly or monthly scales, suggesting that volume is not yet confirming the price moves. This lack of volume confirmation warrants caution, as sustainable rallies typically require strong volume support.
Comparative Returns and Market Context
Alkem Laboratories has outperformed the broader Sensex index over multiple time horizons. Year-to-date, the stock has delivered a 2.07% return compared to the Sensex’s decline of 8.23%. Over one year, Alkem has surged 21.26%, significantly ahead of the Sensex’s 5.52% gain. The outperformance is even more pronounced over longer periods, with a 5-year return of 104.76% versus 52.51% for the Sensex, and a remarkable 10-year return of 317.15% compared to 217.61% for the benchmark.
This strong relative performance underscores Alkem’s resilience and growth potential within the Pharmaceuticals & Biotechnology sector, despite recent technical caution signals.
Mojo Score and Rating Update
MarketsMOJO assigns Alkem Laboratories a Mojo Score of 62.0, reflecting a Hold rating, downgraded from a previous Buy as of 1 December 2025. The Market Cap Grade stands at 2, indicating a mid-cap status with moderate market capitalisation strength. This rating adjustment aligns with the mixed technical signals and suggests investors should adopt a balanced approach, weighing both the stock’s growth prospects and near-term risks.
Investment Implications and Outlook
Investors should note the mildly bullish shift in daily moving averages and monthly MACD as encouraging signs for potential upside. However, the weekly bearish signals from MACD and KST, combined with neutral RSI and lack of volume confirmation, advise prudence. The stock’s proximity to its 52-week high may attract profit-taking, but the broader trend remains constructive.
Given the stock’s strong historical returns relative to the Sensex and its leadership in the Pharmaceuticals & Biotechnology sector, Alkem Laboratories remains a compelling candidate for investors seeking exposure to healthcare innovation and growth. Nonetheless, the current technical landscape suggests monitoring for confirmation of sustained momentum before committing additional capital.
Alkem Laboratories Ltd or something better? Our SwitchER feature analyzes this mid-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Summary
Alkem Laboratories Ltd’s technical parameters have shifted to a cautiously optimistic stance, with daily moving averages and monthly MACD signalling mild bullishness. However, weekly indicators such as MACD and KST remain mildly bearish, and volume-based metrics do not yet confirm the price strength. The stock’s strong relative returns and sector leadership provide a solid fundamental backdrop, but investors should remain vigilant for confirmation of sustained momentum.
Overall, the current technical and fundamental profile supports a Hold rating, consistent with MarketsMOJO’s recent downgrade, suggesting that investors balance potential upside with near-term risks in this mid-cap pharmaceutical stock.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
